{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"POINT Biopharma Announces New Board Appointments - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"pv2Fj3JfOu\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-announces-new-board-appointments\/\">POINT Biopharma Announces New Board Appointments<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-announces-new-board-appointments\/embed\/#?secret=pv2Fj3JfOu\" width=\"600\" height=\"338\" title=\"&#8220;POINT Biopharma Announces New Board Appointments&#8221; &#8212; Market Newsdesk\" data-secret=\"pv2Fj3JfOu\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT \u2019 s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Knight Therapeutics Inc. (TSE:GUD). Mr. Goodman is a recipient of the Globe and Mail\u2019s Top 40 Under &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODcwOCMzODYxNzMxIzIxOTQ1Njg="}